Olaparib is also indicated in combination with bevacizumab for the maintenance treatment of patients with advanced high-grade epithelial ovarian cancer following first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a BRCA1/2 mutation and/or genomic instability. This evidence concerns the gene BRCA1 and cancer.